CD8A and colorectal carcinoma: To address these limitations, we sought to explore alternative prognostic markers based on CD3<sup>+</sup> and CD8<sup>+</sup> quantification in CRC.<h4>Methods</h4>201 resected CRCs were subjected to quantitative CD3/CD8 immunohistochemistry, from which percentile cell counts were averaged ("I-score") in a manner analogous to the ImmunoscoreTM.